Kristie L. Kahl

The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.

Researchers interviewed 24 cancer survivors to discuss the psychosocial aspects of hearing loss and why patients must advocate for themselves with this long-term condition sooner.

Concurrent chemoradiotherapy with proton radiation can reduce short-term side effects that caused unplanned hospitalizations, with similar disease-free and overall survival, compared with photon radiation.

The pivotal phase 3 GRAVITAS-301 study – designed to evaluate itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease – failed to meet its primary endpoint of improving overall response rates.

Patients with previously untreated locally advanced or metastatic urothelial carcinoma treated with Bavencio and best supportive care as a first-line maintenance therapy experienced significantly longer survival.

Treatment with a CAR-T cell therapy showed promise in patients with mantle cell lymphoma, potentially leading to a new option for a group of individuals who have exhausted other options.

Researchers found that combining family history and genetic risk scores to determine inherited risk for prostate cancer could personalize screening strategies for men.

Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.

A modified citrus pectin, naturally found in the peel of citrus fruits, showed continued benefit among men with prostate cancer.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Cesar Rodriguez about precision medicine, and his recent trek to Patagonia with Moving Mountains for Multiple Myeloma.

The American Cancer Society launched a video series to offer support for caregivers to address their questions and concerns throughout their loved one’s cancer journey.

Here is a list of the recent trial initiations that occurred within the cancer space in December.

The Food and Drug Administration approved the first PARP inhibitor for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma.

The Food and Drug Administration’s accelerated approval of Padcev offers patients with advanced bladder cancer a potential standard of care.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Ed Kim to better understand genomics in lung cancer.

Men with metastatic castration-sensitive prostate cancer will now have a fourth treatment option to consider.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Lisa Schlager, from FORCE, about the types of legal protections in place for those with a genetic risk for cancer.

The Food and Drug Administration approved Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

The Food and Drug Administration approved Xtandi for the treatment of patients with metastatic castration-sensitive prostate cancer.

At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.

As a 20-something med student facing a rare disease, Dr. David C. Fajgenbaum took matters into his own hands to find his own treatment.

The Food and Drug Administration approved the first generic for Afinitor, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

The Food and Drug Administration approved Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations.

The FDA accepted a supplemental biologics license application (sBLA) and granted a priority review to Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to AstraZeneca, the drug’s manufacturer.

The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.

Here is a list of the recent trial initiations that occurred within the cancer space in November.

In this week’s “CURE Talks Cancer” podcast, we spoke with Michelle Velez, who developed a rare gynecological cancer following a molar pregnancy.

The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.

The keynote speaker at the CURE® Patient-Focused Sessions at the Annual New York Lung Cancers Symposium® heeded warning signs and urges others to do the same.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Mark Socinski to learn more about stage 3 lung cancer and what others should know about the disease.